Premium
Novel factors that activate and deactivate cardiac fibroblasts: A new perspective for treatment of cardiac fibrosis
Author(s) -
Oliveira Camargo Rebeca,
Abual'anaz Besher,
Rattan Sunil G.,
Filomeno Krista L.,
Dixon Ian M. C.
Publication year - 2021
Publication title -
wound repair and regeneration
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.847
H-Index - 109
eISSN - 1524-475X
pISSN - 1067-1927
DOI - 10.1111/wrr.12947
Subject(s) - cardiac fibrosis , myofibroblast , fibrosis , smad , cancer research , medicine , fibroblast , myocardial fibrosis , fibronectin , transforming growth factor , microbiology and biotechnology , pathology , biology , extracellular matrix , biochemistry , in vitro
Abstract Heart disease with attendant cardiac fibrosis kills more patients in developed countries than any other disease, including cancer. We highlight the recent literature on factors that activate and also deactivate cardiac fibroblasts. Activation of cardiac fibroblasts results in myofibroblasts phenotype which incorporates aSMA to stress fibres, express ED‐A fibronectin, elevated PDGFRα and are hypersecretory ECM components. These cells facilitate both acute wound healing (infarct site) and chronic cardiac fibrosis. Quiescent fibroblasts are associated with normal myocardial tissue and provide relatively slow turnover of the ECM. Deactivation of activated myofibroblasts is a much less studied phenomenon. In this context, SKI is a known negative regulator of TGFb 1 /Smad signalling, and thus may share functional similarity to PPARγ activation. The discovery of SKI's potent anti‐fibrotic role, and its ability to deactivate and/or myofibroblasts is featured and contrasted with PPARγ. While myofibroblasts are typically recruited from pools of potential precursor cells in a variety of organs, the importance of activation of resident cardiac fibroblasts has been recently emphasised. Myofibroblasts deposit ECM components at an elevated rate and contribute to both systolic and diastolic dysfunction with attendant cardiac fibrosis. A major knowledge gap exists as to specific proteins that may signal for fibroblast deactivation. As SKI may be a functionally pluripotent protein, we suggest that it serves as a scaffold to proteins other than R‐Smads and associated Smad signal proteins, and thus its anti‐fibrotic effects may extend beyond binding R‐Smads. While cardiac fibrosis is causal to heart failure, the treatment of cardiac fibrosis is hampered by the lack of availability of effective pharmacological anti‐fibrotic agents. The current review will provide an overview of work highlighting novel factors which cause fibroblast activation and deactivation to underscore putative therapeutic avenues for improving disease outcomes in cardiac patients with fibrosed hearts.